Robeco Institutional Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$287M Buy
460,602
+111,815
+32% +$76.1M 0.35% 56
2026
Q1
$269M Buy
348,787
+86,937
+33% +$66.6M 0.38% 61
2025
Q4
$202M Buy
261,850
+140,966
+117% +$95.7M 0.29% 81
2025
Q3
$68M Buy
120,884
+73,176
+153% +$41.4M 0.1% 203
2025
Q2
$25M Sell
47,708
-64,787
-58% -$36.2M 0.04% 319
2025
Q1
$71.3M Sell
112,495
-16,813
-13% -$11.6M 0.14% 153
2024
Q4
$92.1M Buy
129,308
+1,130
+0.9% +$948K 0.17% 121
2024
Q3
$135M Buy
128,178
+1,243
+1% +$1.38M 0.27% 85
2024
Q2
$133M Buy
126,935
+10,568
+9% +$10.2M 0.29% 73
2024
Q1
$112M Sell
116,367
-3,924
-3% -$3.73M 0.24% 94
2023
Q4
$106M Buy
120,291
+4,758
+4% +$3.92M 0.26% 94
2023
Q3
$95.1M Sell
115,533
-7,312
-6% -$5.75M 0.25% 96
2023
Q2
$88.3M Sell
122,845
-578
-0.5% -$446K 0.23% 102
2023
Q1
$101M Buy
123,423
+375
+0.3% +$283K 0.28% 95
2022
Q4
$88.8M Buy
123,048
+19,598
+19% +$14.5M 0.26% 99
2022
Q3
$71.3M Buy
103,450
+20,690
+25% +$13M 0.23% 102
2022
Q2
$48.9M Buy
82,760
+14,984
+22% +$9.74M 0.15% 144
2022
Q1
$47.3M Buy
67,776
+17,331
+34% +$11M 0.11% 204
2021
Q4
$31.9M Sell
50,445
-8,193
-14% -$5.04M 0.07% 275
2021
Q3
$35.5M Buy
58,638
+21,394
+57% +$13.3M 0.08% 265
2021
Q2
$20.8M Sell
37,244
-75,370
-67% -$38.2M 0.05% 355
2021
Q1
$53.3M Sell
112,614
-45,859
-29% -$22.3M 0.13% 188
2020
Q4
$76.6M Sell
158,473
-15,697
-9% -$8.47M 0.2% 125
2020
Q3
$97.5M Buy
174,170
+19,050
+12% +$11.6M 0.3% 88
2020
Q2
$96.7M Buy
155,120
+119,756
+339% +$68M 0.33% 75
2020
Q1
$17.3M Buy
35,364
+22,290
+170% +$9.19M 0.07% 312
2019
Q4
$4.91M Sell
13,074
-5,122
-28% -$1.72M 0.02% 602
2019
Q3
$5.05M Sell
18,196
-1,150
-6% -$340K 0.02% 588
2019
Q2
$6.06M Sell
19,346
-1,955
-9% -$651K 0.02% 565
2019
Q1
$8.75M Buy
21,301
+7,931
+59% +$3.27M 0.03% 487
2018
Q4
$4.98M Buy
13,370
+7,806
+140% +$2.86M 0.02% 538
2018
Q3
$2.25M Buy
5,564
+1,000
+22% +$381K 0.01% 672
2018
Q2
$1.57M Sell
4,564
-678
-13% -$212K 0.01% 698
2018
Q1
$1.81M Buy
5,242
+4,204
+405% +$1.46M 0.01% 678
2017
Q4
$391K Hold
1,038
﹤0.01% 790
2017
Q3
$463K Buy
1,038
+12
+1% +$5.71K ﹤0.01% 728
2017
Q2
$504K Hold
1,026
﹤0.01% 743
2017
Q1
$398K Sell
1,026
-55
-5% -$20.4K ﹤0.01% 744
2016
Q4
$396K Sell
1,081
-2,302
-68% -$875K ﹤0.01% 672
2016
Q3
$1.36M Sell
3,383
-2,156
-39% -$865K 0.01% 579
2016
Q2
$1.93M Hold
5,539
0.01% 526
2016
Q1
$2M Sell
5,539
-1,262
-19% -$520K 0.02% 500
2015
Q4
$3.69M Buy
6,801
+1,889
+38% +$1.02M 0.03% 384
2015
Q3
$2.29M Buy
4,912
+1,865
+61% +$1M 0.02% 460
2015
Q2
$1.55M Buy
3,047
+650
+27% +$317K 0.01% 530
2015
Q1
$1.08M Buy
2,397
+334
+16% +$142K 0.01% 550
2014
Q4
$846K Buy
+2,063
New +$811K 0.01% 579
2014
Q3
Sell
-1,266
Closed -$358K 778
2014
Q2
$358K Buy
1,266
+650
+106% +$193K ﹤0.01% 634
2014
Q1
$185K Buy
616
+161
+35% +$49.6K ﹤0.01% 618
2013
Q4
$125K Hold
455
﹤0.01% 547
2013
Q3
$142K Hold
455
﹤0.01% 555
2013
Q2
$102K Buy
+455
New +$106K ﹤0.01% 553

Other funds holding REGN

Robeco Institutional Asset Management's REGN Position: Q2 2026 in Review

Robeco Institutional Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2026, buying an estimated $76.1M and bringing the position to 460,602 shares worth $287M. The position accounts for 0.35% of the portfolio, ranked #56.

Robeco Institutional Asset Management first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 267 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Robeco Institutional Asset Management held 460,602 shares of Regeneron Pharmaceuticals worth $287M as of Q2 2026.
  • Robeco Institutional Asset Management bought 111,815 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $76.1M.
  • Regeneron Pharmaceuticals made up 0.35% of Robeco Institutional Asset Management's portfolio in Q2 2026, its #56 holding.
  • Robeco Institutional Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 267 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.